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Abstract There is substantial evidence that cytokines induce
apoptosis of vascular smooth muscle cells (VSMCs) in athero-
sclerosis. Its regulation, however, is not completely de¢ned. The
aim of this study is to investigate whether proteasome activity is
related with apoptosis in VSMCs by tumor necrosis factor-K
(TNF-K). Rat aorta smooth muscle cells were treated with
TNF-K and proteasome inhibitor MG132 and then cell death
was determined by morphology, viability, and DNA fragmenta-
tion. MG132 or TNF-K alone did not induce cell death. In
contrast, co-treatment of TNF-K and proteasome inhibitor in-
duced death and DNA degradation in VSMCs, suggesting pro-
teasome inhibitor enhanced death activity of TNF-K. The death
was not blocked by ascorbic acid but by nitric oxide synthase
inhibitor NG-monomethyl-L-arginine. Both caspase-3 and -8
were activated during the death by the proteasome inhibitor
and TNF-K. The death was e¡ectively blocked by the caspase-
3 inhibitor z-DEVD-fmk, suggesting a role of caspase-3 in the
death. Nonetheless, there were no signi¢cant alterations in the
level of Bcl-2, Bcl-XL, Bax and Bak by the proteasome inhib-
itor, nor any evidence of cytochrome (cyt) c release into cytosol
from dying cells, suggesting that cyt c is not involved. These
results suggest that proteasome inhibition potentiates TNF-
mediated death in VSMCs in a cyt c-independent pathway.
The present study proposes a new mechanism by which VSMCs
undergo death by cytokines.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Atherosclerosis ; Proteasome;
Vascular smooth muscle cell ; Tumor necrosis factor
1. Introduction
Tumor necrosis factor (TNF)-K is a representative of the
family of trimeric cytokines and cell surface proteins such as
Fas ligand (FasL), CD40 ligand, and TNF-K-related apopto-
sis-inducing ligand [1]. Upon binding of ligands, members of
the TNF-K receptor (TNFR) superfamily can induce cell
death. The most widely accepted apoptotic pathway involves
TNFR1-associated death domain protein (TRADD), Fas-as-
sociated death domain-containing protein (FADD), and cas-
pases. Binding of TNF-K to its receptor, TNFR1, induces
receptor trimerization and recruitment of several signaling
proteins to the cytoplasmic domains of the receptors. Among
the recruited proteins, TRADD, FADD, and caspase-8 are
associated with cell death [2,3]. The recruited caspase-8 is
activated by cleavage of the N-terminal prodomain, which
in turn leads to activation of downstream caspases such as
caspase-3 [4]. Although ligand binding of TNFR1 can trigger
cellular apoptosis, there is evidence that TNF-K itself has little
e¡ect on the apoptosis of vascular smooth muscle cells
(VSMCs) [5]. In addition to apoptosis, exposure of cells to
TNF-K can result in activation of transcription factors AP-1
and NF-UB that induce gene expression [2,3]. The activation
of NF-UB requires degradation of its inhibitor protein IUB. In
response to TNF-K, the IUBs are phosphorylated by the IUB
kinase complex, resulting in the ubiquitination, degradation
by proteasome, and nuclear translocation of freed NF-UB [2].
Some genes induced by NF-UB act to suppress TNF-K-in-
duced apoptosis, thereby explaining why the apoptotic re-
sponse to TNF-K is usually dependent on inhibition of
RNA or protein synthesis [6,7]. Still the mechanism of death
in VSMCs by cytokines remains obscure.
The ubiquitin/proteasome system is the main non-lysosomal
route for intracellular protein degradation. It is instrumental
to regulation of various cellular processes, such as cell cycle
progression, antigen processing, and cell death [8]. The role of
proteasome in cell death was investigated with various pro-
teasome inhibitors. Proteasome inhibitors seem to be able to
trigger both the intrinsic apoptotic pathway [9,10] and the
receptor-mediated apoptotic pathway [11,12]. In human
VSMCs, proteasome inhibitors increased susceptibility to
FasL. The ability of proteasome inhibitors to sensitize vascu-
lar smooth muscle cells to FasL raised the question as to
whether proteasome inhibitor can do the same in another
member of the TNF family. The present study demonstrated
that inhibition of proteasome function resulted in the en-
hancement of death activity of TNF-K in VSMCs without
release of cytochrome (cyt) c.
2. Materials and methods
2.1. Cell culture
Rat aorta smooth muscle cells were grown in Dulbecco’s modi¢ed
Eagle’s medium-high glucose (DMEM) (Life Technology, Grand Is-
land, NY, USA) supplemented with 10% fetal bovine serum (FBS),
5 mM L-glutamine, plus 50 U/ml penicillin and 50 Wg/ml streptomycin
in a humidi¢ed atmosphere of 5% CO2.
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2.2. Antibodies and reagents
MG132 was purchased from Calbiochem (La Jolla, CA, USA).
z-Asp-Glu-Val-Asp-£uoromethylketone (z-DEVD.fmk) was obtained
from Enzyme Systems Products (Livermore, CA, USA). Antibodies
for Bcl-2, Bcl-XL, Bax and Bak were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Monoclonal antibody for cyt c was from
PharMingen (San Diego, CA, USA). Antibody for activated cas-
pase-3 was obtained from Cell Signaling Technology (Beverly, MA,
USA). Cytokines were obtained from RpD systems (Minneapolis,
MN, USA). All other reagents were obtained from Sigma Chemical
Co. (St. Louis, MO, USA).
2.3. Measurement of viability
Cell viability was determined by exclusion of trypan blue. At the
indicated times after treatment with reagents, cells were detached with
trypsin, pelleted, and resuspended in DMEM containing 1% FBS.
After staining with trypan blue, viable cells in ¢ve random ¢elds of
view were counted. The percentage of treated viable cells was deter-
mined as a percentage of control viability.
2.4. Enzyme assay of oligonucleosomes
Oligonucleosomes in cells treated with appropriate reagents were
quantitatively determined with the cell death detection ELISAPLUS
kit (Roche, Indianapolis, IN, USA).
2.5. Activities of caspase-8 and -3
The activities of caspase-8 and -3 were examined using colorimetric
methods following the manufacturer’s instructions (Clontech, Palo
Alto, CA, USA).
2.6. Western blot analysis
Cells were lysed in a lysis bu¡er (50 mM Tris^HCl, pH 7.8, 150 mM
NaCl, 1% NP40, 0.1% SDS, 1 mM phenylmethylsulfonyl £uoride
(PMSF)). The lysates were resolved on SDS^PAGE gels, followed
by transfer to polyvinylidene di£uoride membranes. Membranes
were blocked in Tris-bu¡ered solution (50 mM Tris^HCl, pH 7.4,
150 mM NaCl, 0.1% Tween-20) containing 5% non-fat dry milk,
and then incubated with primary antibodies for 1^2 h. Membranes
were washed and incubated with horseradish peroxidase-conjugated
secondary antibodies. Chemiluminescent signals were imaged on
X-ray ¢lms.
2.7. Preparation of mitochondrial and S100 cytosol fractions
Cells were washed with phosphate-bu¡ered saline and incubated in
bu¡er A (20 mM HEPES, pH 7.5/10 mM KCl/1.5 mM MgCl2/1 mM
EDTA/1 mM EGTA/1 mM dithiothreitol/0.1 mM PMSF) containing
250 mM sucrose and homogenized by 10 strokes with a Te£on ho-
mogenizer. After centrifugation of homogenate twice at 750Ug for 10
min at 4‡C, the supernatants were centrifuged at 10 000Ug for 15 min
at 4‡C. The pellets were collected, resuspended in bu¡er A containing
sucrose (250 mM), and kept frozen at 370‡C. The resulting super-
natants were further centrifuged at 100 000Ug for 1 h at 4‡C and the
resulting supernatants (S100 cytosolic fraction) were also frozen at
370‡C. Cyt c in mitochondrial and cytosolic fractions were immuno-
logically probed by Western blotting.
3. Results
3.1. Death in VSMCs by TNF-K is induced in the presence of
proteasome inhibitor
To investigate whether proteasome inhibition a¡ected death
signal by TNF-K, the proteasome inhibitor MG132 was uti-
lized. MG132 e⁄ciently blocked proteasome activity in eu-
karyotic cells [13,14]. The morphological appearance of
VSMCs treated for 24 h with indicated reagents was examined
(Fig. 1). Cells treated with TNF-K (A) or MG132 (B) alone
remained attached to tissue culture plates. However, a large
number of cells treated with both TNF-K and proteasome
inhibitor (C) detached and were £oating in the medium. The
detachment was profoundly blocked by the caspase inhibitor
z-DEVD (D). To assess the extent of cell death by the treat-
ment, cell viability was determined at indicated time points
(Fig. 2). TNF-K did not a¡ect the viability, which is consistent
with the ¢ndings by Geng et al. [5]. MG132 alone slightly
a¡ected viability without statistical signi¢cance, whereas si-
multaneous treatment with TNF-K and MG132 dramatically
decreased viability in a time-dependent manner. Cell death
was markedly increased at 24 h after treatment (P6 0.01).
The data demonstrated that in the presence of proteasome
inhibitor, TNF-K induced death of VSMCs. The cell death,
however, was signi¢cantly blocked by z-DEVD (P6 0.01).
It was investigated whether degradation of DNA occurred
by measuring the amount of mono- or oligonucleosomes com-
prising DNA fragments and histones (Fig. 3). Treatment with
MG132 or TNF-K alone showed trivial e¡ects on DNA frag-
mentation. Compared to cells treated with TNF-K or protea-
some inhibitor alone, profoundly increased amounts of mono-
or oligonucleosomes were detected in cells co-treated with
TNF-K and proteasome inhibitor (P6 0.01). z-DEVD signi¢-
cantly inhibited the production of oligonucleosomes
(P6 0.01). The data indicate that apoptosis might be induced
by TNF-K, as the release of DNA fragments and histones is
the key feature in apoptosis [15]. The death in VSMCs by
oxidized low density lipoprotein and cytokines was blocked
by ascorbic acid [16] and nitrogen oxide synthase inhibitor [5],
respectively. Thus, it was investigated whether TNF-K-in-
duced apoptosis was in£uenced by ascorbic acid or NG-mono-
methyl-L-arginine (L-NMMA) (Fig. 3). Cells were pre-treated
with either ascorbic acid or L-NMMA before they were ex-
posed to MG132 and TNF-K. Pre-treatment with ascorbic
acid did not alter death in VSMCs. The death, however,
was signi¢cantly inhibited by the nitric oxide synthase inhib-
itor L-NMMA (P6 0.05).
3.2. TNF-K and proteasome inhibitor activate caspase-3 and -8
Since caspase-3 inhibitor blocked the death and DNA frag-
mentation by TNF-K, it was investigated whether TNF-K and
proteasome inhibitor activated caspases. The activities of cas-
pase-3 and -8 in the cell lysates were determined at indicated
Fig. 1. Morphology of VSMCs treated with TNF-K and proteasome
inhibitor. VSMCs were treated with proteasome inhibitor (0.1 WM)
alone, or co-treated with TNF-K (50 ng/ml) and proteasome inhibi-
tor with or without z-DEVD (50 WM). Cells were incubated for 24 h
and photographed. Magni¢cation 200U. A: TNF-K. B: MG132.
C: MG132+TNF-K. D: MG132+TNF-K+z-DEVD.
FEBS 26923 17-1-03
H.H. Kim, K. Kim/FEBS Letters 535 (2003) 190^194 191
time points (Fig. 4A). The caspase-8 activity was detected at
6 h post treatment, reached a maximum at 12 h after treat-
ment, and decreased thereafter. The increased caspase-8 activ-
ity was followed by activation of caspase-3. The caspase-3
activity was observed at 9 h post treatment and increased
up to 20 h after treatment. Furthermore, the active (cleaved)
form of caspase-3 was detected in VSMCs by Western blot
analysis after cells were co-treated with TNF-K and MG132
(Fig. 4B). The cleaved caspase-3 was detected at 9 h after the
co-treatment. Thereafter, the immunoreactive cleaved caspase-
3 increased in a time-dependent manner.
3.3. Proteasome inhibition does not a¡ect Bcl-2 family proteins
The susceptibility to apoptosis is determined by the ratio of
the positive regulators (Bak, Bax, and Bcl-XS) to negative
regulators (Bcl-2, Bcl-XL, Mcl-1, and A1) of the Bcl-2 family
[17]. It has been reported that proteasome inhibition was fol-
lowed by accumulation of pro-apoptotic Bax in Jurkat cells
[18]. Therefore, it was determined whether proteasome inhibi-
tion potentiated TNF-K-mediated death by modifying the
amount of anti- or pro-apoptotic Bcl-2 family proteins (Fig.
5A). To investigate this, the levels of Bcl-2 family proteins in
response to the proteasome inhibitor were examined. As
shown in the ¢gure, there was no evidence of signi¢cant
changes in immunoreactivity levels of Bcl-2, Bcl-XL, Bax,
and Bak in cells treated with MG132.
Fig. 2. Viability of VSMCs treated with TNF-K and proteasome in-
hibitor. Rat VSMCs were incubated for 6, 12, 18, and 24 h with
MG132 (0.1 WM) alone, or co-incubated with TNF-K (50 ng/ml)
and MG132 in the presence or absence of z-DEVD (50 WM). Viable
cells were counted after staining with trypan blue. The viability of
untreated control cells was counted as 100%. The viability of treated
cells was expressed as a percentage of control cells. Data represent
average of four experiments. *P6 0.01 at 24 h.
Fig. 3. Enrichment of nucleosomes in dying VSMCs. After pre-
treatment with or without ascorbic acid (100 WM) or L-NMMA
(500 WM) for 12 h, VSMCs were exposed for 24 h to proteasome
inhibitor alone, or TNF-K and proteasome inhibitor in the absence
or presence of z-DEVD. The fragmented nucleosomes in cell culture
supernatant and cell lysate were analyzed using ELISAPLUS. The ex-
tent of DNA fragmentation was expressed as absorbance at 405
nm. The data are presented as meanTS.D. of triplicate cultures.
The concentrations of proteasome inhibitor, TNF-K, and
z-DEVD.fmk were 0.1 WM, 50 ng/ml, and 50 WM, respectively.
*P6 0.01, **P6 0.05.
Fig. 4. Activation of caspase-3 and -8. A: Cell lysates were prepared
from the VSMCs treated with 0.1 WM MG132 and 50 ng/ml TNF-K
for indicated periods of time. The activities of caspase-3 and -8 in
the lysates were determined by colorimetric methods. The activities
of untreated control cells were counted as 100%. The activities of
caspase-3 and -8 in the treated cells were expressed as a percentage
of control cells. B: Cells were co-treated with MG132 and TNF-K.
The lysates were prepared at indicated time points and were sub-
jected to Western blot analysis with an antibody which recognizes
the active form of caspase-3.
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3.4. Cyt c is not released from dying VSMCs
TNF-K and Fas treatment can trigger cleavage of Bid by
caspase-8, and the cleaved Bid inserts into the mitochondrial
membrane, resulting in cyt c release [19,20]. The released cyt c
activates e¡ector caspases including caspase-3 and -7 [21]. We
observed activation of caspase-8 and -3 in dying cells. Thus, it
was investigated whether cyt c played a role in the activation
of caspase-3 by examining release of cyt c into cytosol (Fig.
5B). Cyt c was detected in mitochondrial fractions and the cyt
c in mitochondrial fraction was not changed before and after
treatment with TNF-K and MG132 (panel a). The immuno-
reactive cyt c, however, was not detected in S100 cytosolic
fractions (panel b). As a positive control, the cytosolic frac-
tion of VSMCs treated with a cytokine mixture of TNF-K,
interferon-Q, and interleukin (IL)-1L was included. Liu et al.
[21] reported that the treatment with the cytokine mixture
caused release of cyt c into cytosol. In agreement with the
¢nding by Liu et al. [21] cyt c was detected in the cytosolic
fraction of the cytokine-treated cells. The data suggest that cyt
c is not involved in the activation of caspase-3 while VSMCs
undergo death by TNF-K and proteasome inhibition.
4. Discussion
Proteasome inhibition can be pro- or anti-apoptotic de-
pending on cell type and proliferative state of the cells. For
example, proteasome inhibitors protected cells from apoptosis
induced by some but not all stimuli. Programmed cell death of
sympathetic neurons upon deprivation of nerve growth factor
was delayed by proteasome inhibitors [22]. In thymocytes,
proteasome inhibition blocked apoptosis induced by ionizing
radiation, glucocorticoids, or phorbol esters [23]. In contrast,
proteasome inhibitors elicited apoptosis in Rat-1 cells, PC12
cells [9], and human leukemic HL60 cells [10]. This study
showed that proteasome inhibition is pro-apoptotic in
VSMCs, as the proteasome inhibitor sensitized cells to
TNF-K-mediated death. The data indicate that proteasome
inhibitor can regulate cell viability by activation of receptor-
mediated death pathways. This ¢nding concurs with that by
Masdehors et al., who reported that proteasome inhibitors
sensitized chemoresistant and radioresistant human CLL lym-
phocytes to TNF-K-induced apoptosis [11]. Apoptosis by Fas,
a member of the TNF receptor family, in human VSMCs was
induced by the proteasome inhibitors MG132 and MG115
[12]. Taken together, these results indicate that proteasome
inhibition can alter viability of cells either by triggering in-
trinsic apoptosis or by activating receptor-mediated death or
both.
It is well known that proteasome inhibitors inactivate NF-
UB transcriptional activity by preventing degradation of IUB
[13]. The inactivation of NF-UB would contribute to death in
VSMCs. This view is supported by the fact that overexpres-
sion of IUB triggered apoptosis of VSMCs by TNF-K [24]. We
were interested in what mechanisms other than NF-UB pro-
teasome inhibition would induce death in VSMCs by TNF-K.
Apoptosis is regulated by inciting signals, the Bcl-2 family of
proteins, and e¡ector caspase-8 and is determined by the rel-
ative amounts of pro- and anti-apoptotic proteins. It was
previously reported that proteasome inhibitors did not change
the level of caspase-3 and -8 in human VSMCs [12]. The
alteration in the expression of Bcl-2 family protein appeared
to be related to apoptosis of VSMCs in atherosclerosis. In the
apoptotic cells of endarterectomy and atherectomy specimens,
there was increased expression of pro-apoptotic Bax and Bak
coupled with a paucity of Bcl-2 and lack of Bcl-XL [25]. Bax
induced cyt c release from mitochondria. In contrast, Bcl-2
prevented release of cyt c [26]. Bak accelerated cell death
following IL-3 withdrawal and inhibited the protective action
of both Bcl-2 and Bcl-XL [27,28]. It is, however, unknown
what factors regulate the expression of Bcl-2 family proteins.
Furthermore, little is known as to whether proteasome inhi-
bition in£uences the expression of Bcl-2 family in VSMCs.
The investigation of the presence or absence of a single pro-
tein from this group in cells would not provide complete in-
formation on the regulation of apoptosis as the roles of indi-
vidual proteins are likely to be speci¢c for di¡erent cells [29].
Therefore, we investigated whether proteasome is a regulatory
factor of the Bcl-2 family in VSMCs. When the expression of
four proteins ^ Bcl-2, Bcl-XL, Bak, and Bax ^ was determined,
there was no appreciable change of the proteins by protea-
some inhibitor. The data suggest that proteasome inhibition is
not associated with degradation of the Bcl-2 family in
VSMCs.
We showed that TNF-K activated caspase-8 and -3 and that
the death in VSMCs by TNF-K was suppressed by caspase-3
inhibition. These results suggest that induction of caspase-3
activity is a candidate for the mechanism underlying the sen-
sitization to TNF-K by proteasome inhibitor. Caspase-3 can
be activated at least by two pathways [4,19]. The pathway,
Fig. 5. Immunoblot analysis of Bcl-2 family proteins and cyt c in
VSMCs. A: The cells were incubated with 0.1 WM MG132 for indi-
cated periods of time. The cells were lysed as described in Section 2.
The lysates were subjected to Western blot analysis using antibodies
against Bcl-2 family proteins. B: Cells were treated with TNF-K (50
ng/ml) and MG132 (0.1 WM) for indicated periods or with a cyto-
kine mixture (CM) of TNF-K, interferon-Q, and IL-1L as described
[21]. Fractions of mitochondria and S100 cytosol were prepared.
The presence of cyt c in the fraction was examined.
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type I or type II, depends not only on the apoptotic stimuli
but also on the cell type. In addition, there is cross-talk be-
tween the two pathways. In type I cells, large amount of
caspase-8 formed at the death-inducing signal complex are
su⁄cient to activate caspase-3 and cell death. The anti-apo-
ptotic protein Bcl-2 has no e¡ect on the activation of caspase-
8 and -3. In type II cells, caspase-3 is primarily activated
downstream of mitochondria, and apoptosis is blocked by
Bcl-2. Activated caspase-8 elicits release of cyt c in the inter-
membrane space of mitochondria into cytosol. The released
cyt c binds with other molecules to form apoptosome com-
plex. The apoptosome complex activates e¡ector caspases
such caspase-3 and -7 via caspase-9 [30]. We determined
whether mitochondria played a role in the death by detecting
release of cyt c into cytosol. The data in the present study
suggest that mitochondria are unlikely to be involved in the
death of VSMCs by proteasome inhibition and TNF-K, as cyt
c was not released from mitochondria of dying cells.
In the current study, we have investigated the relation be-
tween the proteasome system and the TNF pathway and re-
port that (i) proteasome inhibition induces TNF-K-dependent
death in VSMCs by up-regulation of caspase activity; (ii) the
expression of Bcl-2 family proteins is not in£uenced by pro-
teasome inhibition; and (iii) cyt c is not released from the
dying VSMCs into cytosol.
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